Instrument Inactif

Autres langues BioTime, Inc. Nyse

Actions

US09066L1052

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Lineage Cell Therapeutics : Changes in Registrant’s Certifying Accountant	17/06
Lineage Cell Therapeutics : Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holder	17/06
Lineage to Present at 2024 BIO International Convention	30/05
Lineage Cell Therapeutics : FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP CULLEY BRAIN M	29/05
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium	21/05
Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium	21/05
Lineage Cell Therapeutics : Opinion of Sheppard Mullin Richter & Hampton, LLP relating to the legality of the ATM Shares	21/05
Lineage Cell Therapeutics : Prospectus disclosing information, facts, events	21/05
Lineage Cell Therapeutics : Immediate Report	11/05
Lineage Cell: Q1 Earnings Snapshot	09/05
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, vs. Street Est of $1.36M	09/05
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
LINEAGE CELL - OPREGEN PHASE 1/2A CLINICAL STUDY 24-MONTH VISUAL ACUITY RESULTS FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT	07/05
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit	06/05
Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit	06/05
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024	02/05
LINEAGE RECEIVES GRANT FROM CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE	01/05
Lineage Cell Therapeutics : Immediate Report	30/04
Lineage Cell Therapeutics : Additional proxy soliciting materials - definitive	30/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BioTime, Inc. Nyse

Actions

US09066L1052

Autres langues

Filtres